Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses

Abstract Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The understanding of the transmission and the duration of viral shedding in SARS-CoV-2 infection is still limited. Objectives To assess the timeframe...

Full description

Bibliographic Details
Main Authors: Hedvig Glans, Sara Gredmark-Russ, Mikaela Olausson, Sara Falck-Jones, Renata Varnaite, Wanda Christ, Kimia T. Maleki, Maria Lind Karlberg, Sandra Broddesson, Ryan Falck-Jones, Max Bell, Niclas Johansson, Anna Färnert, Anna Smed-Sörensen, Jonas Klingström, Andreas Bråve
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-021-06202-8
id doaj-e00d500b4df24c6084920650bc15165e
record_format Article
spelling doaj-e00d500b4df24c6084920650bc15165e2021-05-30T11:08:50ZengBMCBMC Infectious Diseases1471-23342021-05-012111910.1186/s12879-021-06202-8Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responsesHedvig Glans0Sara Gredmark-Russ1Mikaela Olausson2Sara Falck-Jones3Renata Varnaite4Wanda Christ5Kimia T. Maleki6Maria Lind Karlberg7Sandra Broddesson8Ryan Falck-Jones9Max Bell10Niclas Johansson11Anna Färnert12Anna Smed-Sörensen13Jonas Klingström14Andreas Bråve15Department of Infectious Diseases, Karolinska University HospitalDepartment of Infectious Diseases, Karolinska University HospitalDepartment of Microbiology, Public Health Agency of SwedenDivision of Immunology and Allergy, Department of Medicine Solna, Karolinska InstitutetCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska InstitutetCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska InstitutetCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska InstitutetDepartment of Microbiology, Public Health Agency of SwedenDepartment of Microbiology, Public Health Agency of SwedenDepartment of Perioperative Medicine and Intensive Care, Karolinska University HospitalDepartment of Perioperative Medicine and Intensive Care, Karolinska University HospitalDepartment of Infectious Diseases, Karolinska University HospitalDepartment of Infectious Diseases, Karolinska University HospitalDivision of Immunology and Allergy, Department of Medicine Solna, Karolinska InstitutetCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska InstitutetDepartment of Microbiology, Public Health Agency of SwedenAbstract Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The understanding of the transmission and the duration of viral shedding in SARS-CoV-2 infection is still limited. Objectives To assess the timeframe and potential risk of SARS-CoV-2 transmission from hospitalized COVID-19 patients in relation to antibody response. Method We performed a cross-sectional study of 36 COVID-19 patients hospitalized at Karolinska University Hospital. Patients with more than 8 days of symptom duration were sampled from airways, for PCR analysis of SARS-CoV-2 RNA and in vitro culture of replicating virus. Serum SARS-CoV-2-specific immunoglobulin G (IgG) and neutralizing antibodies titers were assessed by immunofluorescence assay (IFA) and microneutralization assay. Results SARS-CoV-2 RNA was detected in airway samples in 23 patients (symptom duration median 15 days, range 9–53 days), whereas 13 patients were SARS-CoV-2 RNA negative (symptom duration median 21 days, range 10–37 days). Replicating virus was detected in samples from 4 patients at 9–16 days. All but two patients had detectable levels of SARS-CoV-2-specific IgG in serum, and SARS-CoV-2 neutralizing antibodies were detected in 33 out of 36 patients. Total SARS-CoV-2-specific IgG titers and neutralizing antibody titers were positively correlated. High levels of both total IgG and neutralizing antibody titers were observed in patients sampled later after symptom onset and in patients where replicating virus could not be detected. Conclusions Our data suggest that the presence of SARS-Cov-2 specific antibodies in serum may indicate a lower risk of shedding infectious SARS-CoV-2 by hospitalized COVID-19 patients.https://doi.org/10.1186/s12879-021-06202-8COVID-19SARS-CoV-2Viral sheddingCultureAntibodies
collection DOAJ
language English
format Article
sources DOAJ
author Hedvig Glans
Sara Gredmark-Russ
Mikaela Olausson
Sara Falck-Jones
Renata Varnaite
Wanda Christ
Kimia T. Maleki
Maria Lind Karlberg
Sandra Broddesson
Ryan Falck-Jones
Max Bell
Niclas Johansson
Anna Färnert
Anna Smed-Sörensen
Jonas Klingström
Andreas Bråve
spellingShingle Hedvig Glans
Sara Gredmark-Russ
Mikaela Olausson
Sara Falck-Jones
Renata Varnaite
Wanda Christ
Kimia T. Maleki
Maria Lind Karlberg
Sandra Broddesson
Ryan Falck-Jones
Max Bell
Niclas Johansson
Anna Färnert
Anna Smed-Sörensen
Jonas Klingström
Andreas Bråve
Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
BMC Infectious Diseases
COVID-19
SARS-CoV-2
Viral shedding
Culture
Antibodies
author_facet Hedvig Glans
Sara Gredmark-Russ
Mikaela Olausson
Sara Falck-Jones
Renata Varnaite
Wanda Christ
Kimia T. Maleki
Maria Lind Karlberg
Sandra Broddesson
Ryan Falck-Jones
Max Bell
Niclas Johansson
Anna Färnert
Anna Smed-Sörensen
Jonas Klingström
Andreas Bråve
author_sort Hedvig Glans
title Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
title_short Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
title_full Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
title_fullStr Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
title_full_unstemmed Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
title_sort shedding of infectious sars-cov-2 by hospitalized covid-19 patients in relation to serum antibody responses
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2021-05-01
description Abstract Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The understanding of the transmission and the duration of viral shedding in SARS-CoV-2 infection is still limited. Objectives To assess the timeframe and potential risk of SARS-CoV-2 transmission from hospitalized COVID-19 patients in relation to antibody response. Method We performed a cross-sectional study of 36 COVID-19 patients hospitalized at Karolinska University Hospital. Patients with more than 8 days of symptom duration were sampled from airways, for PCR analysis of SARS-CoV-2 RNA and in vitro culture of replicating virus. Serum SARS-CoV-2-specific immunoglobulin G (IgG) and neutralizing antibodies titers were assessed by immunofluorescence assay (IFA) and microneutralization assay. Results SARS-CoV-2 RNA was detected in airway samples in 23 patients (symptom duration median 15 days, range 9–53 days), whereas 13 patients were SARS-CoV-2 RNA negative (symptom duration median 21 days, range 10–37 days). Replicating virus was detected in samples from 4 patients at 9–16 days. All but two patients had detectable levels of SARS-CoV-2-specific IgG in serum, and SARS-CoV-2 neutralizing antibodies were detected in 33 out of 36 patients. Total SARS-CoV-2-specific IgG titers and neutralizing antibody titers were positively correlated. High levels of both total IgG and neutralizing antibody titers were observed in patients sampled later after symptom onset and in patients where replicating virus could not be detected. Conclusions Our data suggest that the presence of SARS-Cov-2 specific antibodies in serum may indicate a lower risk of shedding infectious SARS-CoV-2 by hospitalized COVID-19 patients.
topic COVID-19
SARS-CoV-2
Viral shedding
Culture
Antibodies
url https://doi.org/10.1186/s12879-021-06202-8
work_keys_str_mv AT hedvigglans sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT saragredmarkruss sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT mikaelaolausson sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT sarafalckjones sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT renatavarnaite sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT wandachrist sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT kimiatmaleki sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT marialindkarlberg sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT sandrabroddesson sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT ryanfalckjones sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT maxbell sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT niclasjohansson sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT annafarnert sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT annasmedsorensen sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT jonasklingstrom sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
AT andreasbrave sheddingofinfectioussarscov2byhospitalizedcovid19patientsinrelationtoserumantibodyresponses
_version_ 1721420779926585344